Literature DB >> 15727251

Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis.

Danijela Radivojevic1, Marina Djurisic, Tanja Lalic, Marija Guc-Scekic, Jovan Savic, Predrag Minic, Thalia Antoniadi, Maria Tzetis, Emmanuel Kanavakis.   

Abstract

We have screened 175 patients for molecular defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene using nondenaturing polyacrylamide gel electrophoresis (PAGE), denaturing gradient gel electrophoresis (DGGE), and sequencing. Six different mutations (F508del, G542X, 621+1G --> T, 2789+5G --> A, R1070Q, and S466X) accounted for 79.71% of CF alleles, with the F508del mutation showing a frequency of 72.28%. Another 12 mutations (R334W, 2184insA, I507del, 1525-1G --> A, E585X, R75X, M1I, 457TAT --> G, 574delA, 2723delTT, A120T, and 2907delTT) covered an additional 3.36%. A novel mutation (2723delTT) was found in one CF patient (F508del/2723delTT). Thus, a total of 18 mutations cover 82.57% of CF alleles. During our study, 72% of families at risk for having a CF child were found to be fully informative for prenatal diagnosis. Prenatal diagnosis was performed on 56 families; 76 analyses resulting in 16 affected, 38 carriers, and 22 healthy fetuses. These results imply that the molecular basis of CF in Serbia and Montenegro is highly heterogeneous, as is observed in other eastern and southern European populations. Because we detected more then 80% of CFTR alleles, results could be used for planning future screening and appropriate genetic counseling programs in our country.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15727251     DOI: 10.1089/gte.2004.8.276

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  6 in total

1.  Molecular Heterogeneity in Cystic Fibrosis.

Authors:  Hasret A Civan; Serhat Seyhan
Journal:  J Pediatr Genet       Date:  2020-02-17

2.  Localization studies of rare missense mutations in cystic fibrosis transmembrane conductance regulator (CFTR) facilitate interpretation of genotype-phenotype relationships.

Authors:  Kristina V Krasnov; Maria Tzetis; Jie Cheng; William B Guggino; Garry R Cutting
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

Review 3.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

4.  Identification of 99% of CFTR gene mutations in Bulgarian-, Bulgarian Turk-, and Roma cystic fibrosis patients.

Authors:  Guergana Petrova; Nadezhda Yaneva; Jana Hrbková; Malgorzata Libik; Alexey Savov; Milan Macek
Journal:  Mol Genet Genomic Med       Date:  2019-06-27       Impact factor: 2.183

5.  Analysis of CFTR Gene Mutations in Children with Cystic Fibrosis, First Report from North-East of Iran.

Authors:  Atieh Mehdizadeh Hakkak; Mohammad Keramatipour; Saeid Talebi; Azam Brook; Jalil Tavakol Afshari; Amin Raazi; Hamid Reza Kianifar
Journal:  Iran J Basic Med Sci       Date:  2013-08       Impact factor: 2.699

6.  CFTR mutations spectrum and the efficiency of molecular diagnostics in Polish cystic fibrosis patients.

Authors:  Ewa Ziętkiewicz; Ewa Rutkiewicz; Andrzej Pogorzelski; Barbara Klimek; Katarzyna Voelkel; Michał Witt
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.